Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adventrx phase III colorectal cancer trial gets FDA OK
CoFactor is the company’s biomodulator designed to enhance the activity of the widely used cancer drug 5-fluorouracil (5-FU). The US phase III pivotal clinical trial will be a
CoFactor is the company’s biomodulator designed to enhance the activity of the widely used cancer drug 5-fluorouracil (5-FU). The US phase III pivotal clinical trial will be a
The multi-center, blinded, placebo controlled trial will be conducted in 50 cystic fibrosis (CF) centers in the US, and will evaluate the efficacy and safety of aztreonam lysinate
The office will employ in the region 30 to 40 people by the end of 2006, with research activities related to clinical R&D also managed from Ireland. The
Under the agreement, Aspen will manufacture Gilead’s antiretroviral (ARV) products Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate) for the 95 resource-limited countries included in
The trial is in patients with either advanced bronchioloalveolar carcinoma (BAC) or adenocarcinoma with BAC features that have progressed on or after receiving one to two lines of
The phase III psoriasis trial, named SPIRIT, which commenced in December 2004, includes a total of 453 patients with stable moderate to severe plaque psoriasis. The trial is
According to the company, this novel small molecule anticancer compound potently inhibits receptor tyrosine kinases (RTKs) implicated in tumor proliferation and vascularization. XL820 is the fifth compound to
The agreement is Bentley’s first to develop and license its intranasal spray formulation of insulin. Under the agreement, the two companies have agreed to conduct phase II and
The FDA decision is significant as orphan drug designation creates favorable conditions for the development of drugs for diseases affecting less than 200,000 people in the US, including
If developed as a biopharmaceutical, this improved, highly stable version of IFN-gamma would allow less frequent injections of the drug. The novel molecules, developed using Nautilus’ proprietary technology